BeiGene Ltd. ADR (BGNE) Social Stream
BEIGENE LTD (BGNE) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering BEIGENE LTD.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
---|---|---|---|---|---|---|
2021-11-08 | 6 | $431 | $343.3 | $403.716 | $219.02 | 84.33% |
2022-01-06 | 6 | $431 | $283.3 | $392.46 | $219.02 | 79.19% |
2022-01-12 | 6 | $431 | $283.3 | $388.716 | $219.02 | 77.48% |
2022-01-18 | 6 | $431 | $283.3 | $380.883 | $219.02 | 73.9% |
2022-01-28 | 6 | $431 | $283.3 | $367.55 | $219.02 | 67.82% |
2022-02-08 | 6 | $431 | $283.3 | $354.216 | $219.02 | 61.73% |
2022-02-25 | 6 | $431 | $283.3 | $348.55 | $219.02 | 59.14% |
2022-02-28 | 6 | $431 | $254 | $332.333 | $219.02 | 51.74% |
2022-03-17 | 6 | $431 | $177 | $300.2 | $219.02 | 37.07% |
2022-04-28 | 6 | $431 | $177 | $313.166 | $219.02 | 42.99% |
2022-05-06 | 6 | $431 | $177 | $296.166 | $219.02 | 35.22% |
2022-05-18 | 6 | $431 | $177 | $289.833 | $219.02 | 32.33% |
2022-07-27 | 6 | $431 | $177 | $288.666 | $219.02 | 31.8% |
2022-08-05 | 6 | $431 | $177 | $284.316 | $219.02 | 29.81% |
2022-08-09 | 6 | $431 | $177 | $271.983 | $219.02 | 24.18% |
2022-09-17 | 6 | $431 | $177 | $270.6 | $219.02 | 23.55% |
2022-10-03 | 6 | $431 | $177 | $269.433 | $219.02 | 23.02% |
2022-10-13 | 6 | $296 | $200 | $236.433 | $219.02 | 7.95% |
2022-11-14 | 6 | $296 | $205 | $240.266 | $219.02 | 9.7% |
2022-12-12 | 7 | $296 | $205 | $244.6 | $219.02 | 11.68% |
2022-12-15 | 6 | $302 | $205 | $245.6 | $219.02 | 12.14% |
2023-01-19 | 6 | $302 | $205 | $256.266 | $219.02 | 17.01% |
2023-01-24 | 6 | $325 | $205 | $261.266 | $219.02 | 19.29% |
2023-02-07 | 7 | $325 | $205 | $261.266 | $219.02 | 19.29% |
2023-02-20 | 7 | $325 | $205 | $266.316 | $219.02 | 21.59% |
2023-02-28 | 7 | $321 | $205 | $261.85 | $219.02 | 19.56% |
2023-03-01 | 7 | $350 | $230.1 | $293.35 | $219.02 | 33.94% |
The Trend in the Analyst Price Target
BGNE's average price target has moved up $103.12 over the prior 33 months.
Over the past 46 weeks, BGNE's average upside potential has been 45.14%.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
---|---|---|---|---|---|---|
2022-04-28 | 6 | 431 | 177.0 | 313.166 | 158.45 | 97.64% |
2022-05-09 | 6 | 431 | 177.0 | 289.833 | 134.22 | 115.94% |
2022-07-27 | 6 | 431 | 177.0 | 288.666 | 177.61 | 62.53% |
2023-01-19 | 6 | 302 | 205.0 | 256.266 | 274.50 | -6.64% |
2023-02-28 | 7 | 350 | 230.1 | 294.183 | 224.63 | 30.96% |
BGNE Broker Recommendations Summary
Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
---|---|---|---|---|---|---|
1.29 | 6 | 0 | 1 | 0 | 0 | 7 |
The Trend in the Broker Recommendations
BGNE's average broker recommendation rating improved by 0.54 over the prior 52 weeks.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how BEIGENE LTD fares relative to all US stocks, note that its average analyst price target is higher than 3309.74% of that group.
- BEIGENE LTD's number of analysts covering the stock is greater than 315.93% of stocks in the large market cap category.
- BEIGENE LTD's upside potential (average analyst target price relative to current price) is higher than 693.98% of Pharmaceutical Products stocks.
- In terms of how BEIGENE LTD fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -1142.27% of that group.
Stocks similar to BEIGENE LTD in the Pharmaceutical Products industry regarding analyst recommendations and price targets are GSK, GRFS, and SNY.
View All Top Stocks by Price Target
Is BGNE a Buy, Hold or Sell? See the POWR Ratings now!